Balarishta: Traditional Uses, Evidence & Safety

TL;DR

Balarishta is a fermented Ayurvedic liquid (arishta) named for its chief ingredient, Bala (Sida cordifolia). Practitioners use it for rheumatic pain, weakness, and Vata-type disorders. The modern record holds two small animal studies, a mouse pain experiment and a rat inflammation experiment, plus a high-dose rat study that flagged lipid-profile changes. No human trials exist.

What it is

An arishta is a fermented decoction. Herbs are boiled. Then jaggery (or honey) and fermenting agents such as Dhataki flowers are added. The mixture ferments into a mildly alcoholic liquid. Fermentation is the defining step: it distinguishes arishtas from simple decoctions and is traditionally credited with improving extraction and shelf life.

Balarishta is named for Bala: Sida cordifolia, the "strength" herb. The exact recipe varies by manufacturer and region. The commercial product tested in the 2014 mouse study (Sadhana Oushadhaloy, Dhaka) listed, per 5 ml: 1.2 mg Sida cordifolia roots and 1.2 mg Withania somnifera (Ashwagandha). Plus 2.4 mg Lilium polyphyllum (Kshirakakoli) and 2.4 mg Jatropha gossypifolia (Eranda). The bottle described it as preventing rheumatism and decreasing fever and general weakness (Rahmatullah et al., 2014). Those labeled quantities are strikingly small and differ from classical Indian Balarishta recipes. A reminder that "Balarishta" on a label does not guarantee one standard formula, and that study results on one product do not automatically transfer to another.

Traditional use

The 2014 paper frames Balarishta ethnomedicinally: Ayurvedic practitioners in Bangladesh use it for rheumatic pain. The tested product's own bottle label claimed it prevented rheumatism and decreased fever and general weakness (Rahmatullah et al., 2014). In classical Ayurveda, Bala-based preparations are valued for Vata disorders, debility, and musculoskeletal complaints. The bottle label is a manufacturer's claim, not a clinical finding: treat it accordingly.

What modern research says

Animal experiment: acetic-acid writhing in mice (2014)

Swiss albino mice were divided into groups of five. They were given Balarishta at 0.1, 0.3, 1.0, or 1.5 ml/kg orally, with aspirin (200 mg/kg) as the standard-drug control. Then they were injected with acetic acid to induce abdominal constrictions (a standard pain model). At the three higher doses, Balarishta produced dose-dependent, statistically significant reductions in constrictions, 41.4%, 44.8%, and 55.2% respectively, compared with 37.9% for aspirin. The lowest dose (31.0% reduction) was not significant. Aspirin plus Balarishta together reduced constrictions by 58.6% (Rahmatullah et al., 2014).

This is a genuine antinociceptive (pain-relieving) signal in an animal model. Its limits: five mice per group, a single acute pain model, no human data, and a test product whose formula differs from classical Balarishta. Do not translate mouse ml/kg doses into human dosing: the paper makes no such claim, and neither do we.

Animal experiment: cotton-pellet granuloma in rats (1998)

Alam et al., at the Captain Srinivasa Murti Drug Research Institute for Ayurveda (Madras), screened Balarishta and Dhanvantara Gutika. They tested anti-inflammatory activity against cotton-pellet-induced granuloma in albino rats, with phenylbutazone as the reference drug. Both preparations significantly reduced cotton-pellet (granuloma) weight. Both also significantly reduced liver acid phosphatase, GPT, and GOT activities, and serum acid phosphatase. That is an enzyme pattern the authors interpreted as lysosomal membrane stabilization (Alam et al., Ancient Science of Life 1998).

This is a second, independent animal signal for anti-inflammatory activity. Again in rats, again without human data.

High-dose animal safety signal (2014)

A separate rat study gave Balarishta at 40 ml/kg daily for 28 days to male Sprague-Dawley rats. It reported adverse changes in lipid profile (IOSR Journal of Pharmacy and Biological Sciences 9(4), 2014).

Context matters. 40 ml/kg/day is an enormous dose: orders of magnitude above any human therapeutic dose. So this is a high-dose toxicity signal, not evidence that normal use harms lipid profiles. But it does mean chronic high-dose use produced a measurable adverse metabolic effect in rats, which is worth knowing precisely because human safety data are absent.

What the evidence does not support (yet)

Safety & contraindications

No human safety data exist. Points from the record:

FAQs

What is Balarishta?

A fermented Ayurvedic herbal liquid (arishta) named for Bala (Sida cordifolia), traditionally used for rheumatic pain, weakness, and Vata-type disorders.

Does it relieve pain?

In one small mouse study, it reduced acetic-acid-induced pain responses in a dose-dependent way, performing comparably to aspirin in that model. No human pain trial exists.

Is it safe for long-term use?

Unknown in humans. The only safety data is a rat study at an extremely high dose (40 ml/kg/day for 28 days) that worsened lipid profiles. That is a signal, not a verdict. But it is the only data point available.

Our editorial rule requires a pharmacopoeial or clinical-trial dose. None exists in the available sources, so we state none. The tested commercial product's bottle directed 4 teaspoonfuls daily with water: a manufacturer's direction, not an evidence-based dose, and specific to that product's (weak) formulation.

Annotated Sources

The identity (fermented decoction arishta), ethnomedicinal framing (rheumatic pain use in Bangladesh), tested product composition and bottle label claims, and the full mouse acetic-acid writhing experiment (5 mice/group; 41.4/44.8/55.2% reductions at 0.3/1.0/1.5 ml/kg; 37.9% for aspirin) are from Rahmatullah et al., 2014 (Free Library full text). The 1998 rat granuloma anti-inflammatory study is Alam et al., "Anti-inflammatory potential of Balarishta and Dhanvantara Gutika in albino rats," Ancient Science of Life (PMC full text). The high-dose rat lipid-profile finding (40 ml/kg/day × 28 days, male Sprague-Dawley rats) is from the IOSR Journal of Pharmacy and Biological Sciences 9(4), 2014 (PDF).

Disclaimer

This article is for educational purposes only and is not medical advice. Balarishta has no human trials and no established safety profile; the available evidence is limited to small animal experiments and one high-dose rat safety signal. It is a fermented (mildly alcoholic) liquid whose formula varies between manufacturers. Use only products from reputable manufacturers and only under the supervision of a qualified practitioner — especially if pregnant, breastfeeding, managing a medical condition (including liver disease or lipid disorders), giving it to a child, or taking prescription medicines.